Loading
A phase 3 trial of Mezigdomide, Pomalidomide, Bortezomib in multiple myeloma, run by Celgene, now recruiting.
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT05519085 by Celgene, with 810 participants planned, started 2022-09-20 and due to reach its primary completion in 2027-01-10. Interventions recorded: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Bortezomib, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.